Cabometyx (cabozantinib tablet)

P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

P2, N=200, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting

P1/2, N=234, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting

Selpercatinib conferred significant PFS benefit over SoC in treatment-naïve (1L) patients with RET-mutation-positive MTC, with inconclusive results in the ≥2L setting. Matching retrospective real-world data to prospective trial data is feasible. EC arms to single-arm trials may provide evidence supporting the evaluation of comparative effectiveness.

P2, N=11, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

P2, N=14, Active, not recruiting, Georgetown University | Trial completion date: Dec 2025 --> Dec 2026

P3, N=1175, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Jan 2028 | Trial primary completion date: Sep 2026 --> Jan 2028

Chronic cabozantinib exposure is characterized by sustained suppression of MET phosphorylation and a selective adhesion- and MAPK/AP-1-associated phosphorylation program, accompanied by modest, pattern-specific motility differences observed within the same signaling context. These findings provide a systems level framework for future mechanistic and in vivo evaluation.

P1, N=362, Recruiting, Arcus Biosciences, Inc. | Trial completion date: Jul 2027 --> Mar 2029 | Trial primary completion date: Jul 2027 --> Mar 2029

P=N/A, N=311, Active, not recruiting, Ipsen | Trial primary completion date: May 2026 --> Oct 2025

Therapies using tyrosine kinase inhibitors, such as sunitinib and newer drugs (lenvatinib, surufatinib, cabozantinib), may partially normalize the tumor's disrupted vascular architecture and thus increase its susceptibility to immunological interventions. In the coming years, it will be crucial not only to overcome the immunosuppressive nature of the TME but also to identify predictive biomarkers that will allow for more precise patient selection. This approach may open the way to more effective, personalized therapies for pNENs.

P2, N=19, Terminated, Exelixis | Completed --> Terminated; Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.